Objective To explore the influence of sulfonylurea(SU) on the patients with Type 2 Diabetes and nonlacunar ischemic stroke. Methods Patients with type 2 Diabetes and nonlacunar ischemic stroke met the standardized criteria were included and divided into sulfonylurea(SU) group and Non-SU group. The primary outcomes were the scores of National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (MRS) and Barthel index (BI) evaluated at baseline, the end of 2nd week/discharge and the end of 12th week. We compared these outcomes between SU group and NSU group, as well as among each subgroup of NSU group according to different hypoglycemic medications. We also compared these outcomes between subgroups of SU group according to patient taking SUs alone or combined other hypoglycemic medications. Results After exclusions, the cohort comprised 26 patients taking sulfonylurea before stroke (SU group) and 72 patients not taking sulfonylurea (non-SU group). No significant differences were observed among basic clinical characters, lipid profile, fast blood glucose and HbA1c between SU and non-SU group. No patient died during the 12-week follow-up in either group. No significant differences were observed among all the primary outcomes between SU and non-SU groups. Among non-SU group, the primary outcomes did not show any significant differences in no-medication subgroup, insulin subgroup and metformin subgroup. No significant differences were found between subgroup of SU alone and subgroup of SU combined other medicaiton. Conclusion Sulfonylureas has no hypoglycemic-independent neuropretection function in the patients with Type 2 Diabetes and nonlacunar ischemic stroke.
